New ADC Yields Encouraging Clinical Benefit in Platinum-Resistant Ovarian Cancer
Work presented at AACR showed promising clinical benefit and manageable safety of investigational ADC QLS5132 in Phase I trial patients with platinum-resistant ovarian cancer, achieving over 50% response rates regardless of CLDN6 expression. The post New ADC Yields Encouraging Clinical Benefit in Platinum-Resistant Ovarian Cancer appeared first on GEN - Genetic Engineering and Biotechnology News.
Original Source
Read the full article at Genengnews →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.